XML 31 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1

License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

				Three months ended March 31,
Partner		Drug or Drug Candidate		2018				2017
Baxalta Incorporated/Shire		ADYNOVATE®		$	10,011			$	—
Eli Lilly and Company		NKTR-358			2,354				—
Amgen, Inc.		Neulasta®			1,250				1,250
AstraZeneca AB		MOVANTIK® and MOVANTIK® fixed-dose combination program			—				3,000
Other					112				1,842
License, collaboration and other revenue				$	13,727			$	6,092

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March 31, 2018:

		Three months ended March 31, 2018
Deferred revenue—December 31, 2017		$	37,970
Transition adjustment related to adoption of ASC 606			(1,953	)
Recognition of previously unearned revenue			(3,678	)
Deferred revenue—March 31, 2018		$	32,339

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration